Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Blood

Volumn 123, Issue 17, 2014, Pages 2740-2742

  Sarkozy, Clémentine ^a,b   Seymour, John Francis ^c,d   Ferme, Christophe ^e   Caballero, Dolores ^f   Ghesquieres, Hervé ^g   Leppa, Sirpa ^h   Delarue, Richard ^i,j   Pedersen, Lars Moller ^k   Mounier, Christiane ^l   Da Silva, Maria Gomes ^m   Chassagne Clement, Catherine ^g   Maerevoet, Marie ^n,o   Salles, Gilles ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF SALAMANCA   (Spain)

^g CENTRE LÉON BÉRARD   (France)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k ROSKILDE HOSPITAL   (Denmark)

^l HÔPITAL NORD   (France)

^m INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

ⁿ ERASME HOSPITAL   (Belgium)

^o UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; LACTATE DEHYDROGENASE; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANEMIA; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; DISEASE COURSE; FOLLICULAR LYMPHOMA; HUMAN; INDUCTION CHEMOTHERAPY; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LYMPHOMA CELL; MAINTENANCE CHEMOTHERAPY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; LEUKEMIA; METABOLISM; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; TUMOR EMBOLISM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA; LYMPHOMA, FOLLICULAR; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902105361     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-553693     Document Type: Letter

References (9)

1. International Agency for Research on Cancer. Swerdlow S. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
2. Melo JV, Robinson DS, De Oliveira MP, et al. Morphology and immunology of circulating cells in leukaemic phase of follicular lymphoma. J Clin Pathol. 1988;41(9):951-959.
3. Chubachi A, Miura I, Hashimoto K, et al. High incidence of leukemic phase in follicular lymphoma in Akita, Japan: clinicopathologic, immunological and cytogenetic studies. Eur J Haematol. 1993;50(2):103-109.
4. Rymkiewicz G, Paszkiewicz-Kozik E, Błachnio K, et al. Unusual IgD+/CD38-follicular lymphoma with leukemic presentation. Med Oncol. 2006;23(1):131-135.
5. Al-Nawakil C, Kosmider O, Stern MH, et al. Leukemic phase of follicular lymphomas: an atypical presentation. Leuk Lymphoma. 2011;52(8):1504-1508.
6. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42-51.
7. Sarkozy C, Baseggio L, Feugier P, et al. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. Br J Haematol. 2014;164(5):659-667.
8. Ladetto M, Lobetti-Bodoni C, Mantoan B, et al; Fondazione Italiana Linfomi. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122(23):3759-3766.
9. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642.